Clinical trials: Tocilizumab
B-ALL
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19/CD22 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT04499573
- Testing
- CD19/CD22 CAR-T
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Takayasu Arteritis, Large Vessel Vasculitis
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion.
- Trial name
- STARS (NCT07477795)
- Testing
- Secukinumab, Standard of Care (SOC)
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Juvenile Idiopathic Arthritis
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA).
- Trial name
- NCT01904292
- Testing
- Tocilizumab
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Critical Illness, Corona Virus Infection
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
The cytokine storms mediated by over production of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19.
- Conditions
- Critical Illness, Corona Virus Infection, Cytokine Release Syndrome
- Trial name
- NCT04486521
- Testing
- Interleukin 6 (IL6) Antagonist, Interleukin 6 (IL6) Antagonist and corticosteroids, corticosteroid alone
- Where
- Saudi Arabia
- Volunteers
- 860 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
- Trial name
- Breakfree-SSc (NCT07335562)
- Testing
- BMS-986353, Fludarabine, Cyclophosphamide
- Where
- 56 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juvenile Idiopathic Arthritis
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with…
- Trial name
- NCT02165345
- Testing
- Tocilizumab
- Where
- 31 sites in United States, Argentina and 10 more
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Hematological Malignancy
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T)…
- Trial name
- NCT04082910
- Testing
- Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Polyarticular Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.
- Trial name
- NCT00144625
- Testing
- MRA(Tocilizumab)
- Volunteers
- 19 people
- Sponsor
- Chugai Pharmaceutical
Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis
Clinical Features and Treatment of Systemic JIA in Children
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- CST-SJIA (NCT07814963)
- Testing
- Tocilizumab (Actemra®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Relapsing Polychondritis
Tocilizumab for Relapsing Polychondritis
This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors.
- Trial name
- NCT01104480
- Testing
- Tocilizumab
- Where
- Canada
- Sponsor
- McMaster Children's Hospital
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus).
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Trial name
- COMBAT-NORSE (NCT07281027)
- Testing
- Anakinra, Tocilizumab, Standard medical treatment
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 438 people
- Sponsor
- Yale University
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Trial name
- REMDACTA (NCT04409262)
- Testing
- Remdesivir, Tocilizumab
- Where
- 54 sites in United States, Brazil and 2 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Rheumatology, Cardiovascular Diseases
Cardiovascular Risk and Chronic Inflammatory Rheumatism
Chronic inflammatory rheumatism and inflammation can increase the risk of cardiovascular problems. Indeed, these diseases can increase the risk of myocardial infarction.
- Conditions
- Rheumatology, Cardiovascular Diseases, Arthritis, Rheumatoid, Spondyloarthritis
- Trial name
- RCVRIC (NCT03187444)
- Testing
- Examinations
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Clermont-Ferrand
Juvenile Idiopathic Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study.
- Trial name
- NCT01667471
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Systemic Juvenile Idiopathic Arthritis
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- NCT04088396
- Testing
- Baricitinib, Tocilizumab
- Where
- 55 sites in Argentina, Belgium and 12 more
- Volunteers
- 58 people
- Sponsor
- Eli Lilly and Company
Covid19, Covid-19 ARDS
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04693026
- Testing
- Remdesivir, Baricitinib, Tocilizumab
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- M Abdur Rahim Medical College and Hospital
B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT03467256
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide
- Where
- Russia
- Volunteers
- 18 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Juvenile Idiopathic Arthritis
Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab
Application for Compassionate Use of Tocilizumab in a Boy with Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) Unresponsive to All Licensed Medications.
- Trial name
- NCT00862758
- Testing
- Tocilizumab
- Where
- United States
- Sponsor
- University of Oklahoma
Juvenile Idiopathic Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
This study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active systemic juvenile idiopathic arthritis (sJIA) who have an inadequate clinical response to NSAIDs and corticosteroids.
- Trial name
- NCT00642460
- Testing
- tocilizumab [RoActemra/Actemra], Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate
- Where
- 54 sites in United States, Argentina and 17 more
- Volunteers
- 112 people
- Sponsor
- Hoffmann-La Roche